"The company will achieve its strategic goal of HK$100 billion revenue by 2030 through comprehensive innovation and transformation driven by independent research and development and external introduction. 79 products are expected to be launched in the next three years," said Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm.

On August 24, Sino Biopharm held its first half-year results conference and the first investor day meeting. According to the semi-annual results, Sino Biopharm's first-half revenue reached RMB 15.19 billion, an increase of 5.9% year-on-year.

​

​

Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm

Since this year, Sino Biopharm established four major strategies of "organizational integration, comprehensive innovation, digitalization, internationalization", and accelerated its expansion of internationalization. Miss Tse, Theresa Y Y introduced that the internationalization strategy of Sino Biopharm includes two major parts: "bringing in" and "going out".

In terms of "bringing in", INVOX, a wholly-owned European subsidiary, was established to focus on differentiated dual-antibody, triple-antibody platform, mRNA/DNA and other technologies, and to carry out a comprehensive global strategic layout. In particular, through the cooperation with the research team of Queen's University Belfast in Northern Ireland, we have successfully built a new generation mRNA platform with R&D projects including HPV vaccine and COVID-19 vaccine. The building of the new generation mRNA technology platform also lays the foundation for Sino Biopharm to open up new vaccine projects in the future.

In terms of "going out", Miss Tse, Theresa Y Y introduced that more than 10 innovative drugs and generic drugs have been experiencing clinical trials abroad, and the fastest progress of Anlotinib is expected to be submitted to the U.S. marketing application this year.

Editor: Li Yimeng

Proofreader: Lu Yang